A5030653735- Immune cells in cancer
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Chemokine receptors and signaling
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Acute Myeloid Leukemia Research
- Neuroendocrine Tumor Research Advances
- Sphingolipid Metabolism and Signaling
- BRCA gene mutations in cancer
- Inflammation biomarkers and pathways
- PARP inhibition in cancer therapy
- Immunotherapy and Immune Responses
- Cancer-related cognitive impairment studies
- Estrogen and related hormone effects
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Cancer survivorship and care
- Immune Cell Function and Interaction
- Brain Metastases and Treatment
- ATP Synthase and ATPases Research
- Cancer, Stress, Anesthesia, and Immune Response
The Ohio State University
2016-2025
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2015-2024
Comprehensive Blood & Cancer Center
2024
The Ohio State University Wexner Medical Center
2014-2023
Ohio State University Hospital
2022
Ohio University
2015-2021
Beth Israel Deaconess Medical Center
2019
University of Massachusetts Amherst
2019
Harvard University
2018-2019
Moffitt Cancer Center
2018
Abstract Purpose: mAbs are used to treat solid and hematologic malignancies work in part through Fc receptors (FcRs) on natural killer cells (NK). However, FcR-mediated functions of NK from patients with cancer significantly impaired. Identifying the mechanisms this dysfunction impaired response mAb therapy could lead combination therapies enhance therapy. Experimental Design: Cocultures autologous MDSC were study effect myeloid-derived suppressor (MDSCs) NK-cell including antibody-dependent...
Abstract Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid that expand in tumor-bearing hosts response to soluble factors produced by tumor and stromal cells. MDSC expansion has been linked loss immune effector cell function reduced efficacy immune-based cancer therapies, highlighting the population as an attractive therapeutic target. Ibrutinib, irreversible inhibitor Bruton's tyrosine kinase (BTK) IL2-inducible T-cell (ITK), is clinical use for treatment...
<h3>Importance</h3> Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. <h3>Objective</h3> To determine whether the administration of adjuvant metformin (vs placebo) patients without diabetes improves outcomes. <h3>Design, Setting, Participants</h3> MA.32, phase 3 randomized, placebo-controlled, double-blind trial, conducted Canada, Switzerland, US, UK,...
To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel patients advanced solid tumors.In part this Ib study, 24 tumors received escalating doses pexidartinib (80 mg/m2). Pexidartinib was administered at 600 mg/day cohort 1. For subsequent cohorts, increased by ⩽50% using standard 3+3 design. In 2, 30 metastatic were enrolled to examine tolerability RP2D....
Circulating tumor cells (CTCs) are commonly isolated from the blood by targeting epithelial cell adhesion molecule (EpCAM) through positive selection. However, EpCAM can be downregulated during metastatic progression, or it initially not present. We designed present prospective trial to characterize CTCs as well other circulating populations in samples women with breast cancer without EpCAM-dependent enrichment and/or isolation technology.A total of 32 patients were enrolled, and processed...
Significance The Bromo- and Extra-Terminal (BET) family proteins regulate transcription of several oncogenes. For this reason, targeting BET protein may be a promising strategy for cancer therapy. Checkpoint inhibitors, such as anti–CTLA-4, sustain cytotoxic T cells in their anticancer activity. This paper develops mathematical model to determine the efficacy combination therapy with CTLA-4 inhibitors. Simulations are agreement experimental results. It is shown that two drugs positively...
Hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer is associated with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1, demonstrates poor responses to checkpoint inhibitor therapy. Evaluating the effect standard chemotherapy on immune microenvironment may suggest new opportunities for immunotherapy-based approaches treating HR+/HER2- tumors.HR+/HER2- tumors were analyzed before after neoadjuvant chemotherapy. sTIL assessed histologically; CD8+ cells, CD68+...
This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in heavily pretreated women with receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer, including those gene alpha (
Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key physiologic suppressors of the cytotoxic immune reaction. However, to date, combination PD1/PD-L1 expression tumor-infiltrating lymphocytes (TILs) antigen-presenting cells has been only minimally reported in breast carcinoma, particular relation HER2-positive cases. The goal this study was evaluate both cellular tumoral reaction PD-L1/PD1 distribution cases, as well any associations with clinical outcome using conventional...
Abstract Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia telangiectasia-mutated Rad3-related protein kinase (ATR) inhibitor. We assessed the safety, tolerability, pharmacokinetics, preliminary efficacy of berzosertib plus cisplatin. Methods Adult patients with advanced solid tumours refractory or resistant to standard care therapies received ascending doses cisplatin (day 1) (days 2 9) every 3 weeks (Q3W). Results Thirty-one (90–210...
Abstract Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to failure. This expansion cohort (part C2) previously reported phase 1b trial (NCT02157792) is based on recommended 2 dose combination ataxia-telangiectasia and Rad3-related (ATR) inhibitor berzosertib cisplatin observed in advanced solid tumors, including TNBC. Forty-seven aged ≥18 years TNBC received (75 mg/m ; day...
This first-in-human phase I study (NCT01417546) evaluated the safety profile, optimal immunologic/biological dose (OID/OBD), and immunogenicity of combination two peptide B-cell epitope vaccines engineered to represent trastuzumab- pertuzumab-binding sites. Although trastuzumab pertuzumab have been approved for clinical use, patients often develop resistance these therapies. We advanced a new paradigm in immunotherapy that focuses on humoral responses based conformational vaccines.The...
Abstract Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients metastatic PD-L1 positive triple negative breast cancer (TNBC). anthracycline- taxane-based neoadjuvant also increased pathological complete response (pCR) rates early TNBC. This trial evaluated carboplatin paclitaxel or without atezolizumab clinical stages II-III The co-primary objectives were to evaluate if increase pCR rate tumor infiltrating lymphocyte (TIL) percentage compared...